U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H13NO2
Molecular Weight 131.1729
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOLEUCINE

SMILES

CC[C@H](C)[C@H](N)C(O)=O

InChI

InChIKey=AGPKZVBTJJNPAG-WHFBIAKZSA-N
InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1

HIDE SMILES / InChI

Molecular Formula C6H13NO2
Molecular Weight 131.1729
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00167 | https://www.ncbi.nlm.nih.gov/pubmed/22298573 | https://www.ncbi.nlm.nih.gov/pubmed/4698813 | https://www.ncbi.nlm.nih.gov/pubmed/28089725

Isoleucine is an essential α-amino acid that is used in the biosynthesis of proteins. L-isoleucine is commonly used in parenteral and enteral nutrition. It is used in combination with the other branched chain amino acids to improve the nutritional status of patients with hepatic diseases. BCAAs serve as important fuel sources for skeletal muscle during periods of metabolic stress

Originator

Sources: Biokhim. Chain. Proizv., Akad. Nauk SSSR, Inst. Biokhim., Issue No. 9, Pages 182-4

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FREAMINE III 10%

Approved Use

Parenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance

Launch Date

1971
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.87 μg/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOLEUCINE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21.72 μg × h/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOLEUCINE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.45 h
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOLEUCINE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis.
2001-07-06
A family of yeast proteins mediating bidirectional vacuolar amino acid transport.
2001-06-29
The conserved active site motif A of Escherichia coli DNA polymerase I is highly mutable.
2001-06-01
Role of surface lysine residues of adipocyte fatty acid-binding protein in fatty acid transfer to phospholipid vesicles.
2001-05-29
Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase.
2001-05-22
Acrodermatitis acidemica secondary to malnutrition in glutaric aciduria type I.
2001-05-19
The amino-terminal tail of glycogen phosphorylase is a switch for controlling phosphorylase conformation, activation, and response to ligands.
2001-05-01
Energy utilization of low-protein diets in growing pigs.
2001-05
Why do female Aedes aegypti (Diptera: Culicidae) feed preferentially and frequently on human blood?
2001-05
Enzymology, structure, and dynamics of acetohydroxy acid isomeroreductase.
2001-05
The central enzymes of the aspartate family of amino acid biosynthesis.
2001-05
The internal propeptide of the ricin precursor carries a sequence-specific determinant for vacuolar sorting.
2001-05
Dissociation pathways of alkali-cationized peptides: opportunities for C-terminal peptide sequencing.
2001-05
Does glutamine act as a substrate for transamination reactions in the liver of fed and fasted sheep?
2001-05
Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis.
2001-05
The amino acid residues affecting the activity and azole susceptibility of rat CYP51 (sterol 14-demethylase P450).
2001-05
A single residue differentiates between human cardiac and skeletal muscle Na+ channel slow inactivation.
2001-05
Structural and thermodynamic analysis of the binding of solvent at internal sites in T4 lysozyme.
2001-05
Inhibition of dipeptidyl peptidase IV (DP IV, CD26) activity abrogates stress-induced, cytokine-mediated murine abortions.
2001-05
Tyrosine 331 and phenylalanine 334 in Clostridium perfringens alpha-toxin are essential for cytotoxic activity.
2001-04-27
Superoxide reductase from Desulfoarculus baarsii: reaction mechanism and role of glutamate 47 and lysine 48 in catalysis.
2001-04-24
Vanilloid and isovanilloid analogues as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases.
2001-04-23
Ester and hydroxamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases.
2001-04-23
Roles of histidine residues in tobacco acetolactate synthase.
2001-04-20
Dependence of the bi-functional nature of a sialyltransferase from Neisseria meningitidis on a single amino acid substitution.
2001-04-20
Mechanism of dihydropyridine interaction with critical binding residues of L-type Ca2+ channel alpha 1 subunits.
2001-04-20
Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection.
2001-04-13
Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
2001-04-10
Recombinant tyrosine aminotransferase from Trypanosoma cruzi: structural characterization and site directed mutagenesis of a broad substrate specificity enzyme.
2001-04-07
Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
2001-04-04
Leucine and protein metabolism in rats with chronic renal insufficiency.
2001-04
Activation of skeletal muscle protein breakdown following consumption of soyabean protein in pigs.
2001-04
Involvement of branched-chain amino acid aminotransferases in the production of fusel alcohols during fermentation in yeast.
2001-04
Trans-(DL-isoleucinato-N,O)[tris(2-aminoethyl)amine-kappa(4)N]cobalt(III)diperchlorate..
2001-04
Aspartate kinase 2. A candidate gene of a quantitative trait locus influencing free amino acid content in maize endosperm.
2001-04
Identification of amino acid residues responsible for the alpha5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABA(A) receptor.
2001-04
Identification of a novel COCH mutation, I109N, highlights the similar clinical features observed in DFNA9 families.
2001-04
Regulation of a Rho-associated kinase expression during the corneal epithelial cell cycle.
2001-04
[Significance of trypsinogen gene mutations in the etiology of hereditary pancreatitis].
2001-03-25
New auxiliaries for copper-catalyzed asymmetric Michael reactions: generation of quaternary stereocenters at room temperature.
2001-03-02
Dethiosulfovibrio russensis sp. nov., Dethosulfovibrio marinus sp. nov. and Dethosulfovibrio acidaminovorans sp. nov., novel anaerobic, thiosulfate- and sulfur-reducing bacteria isolated from 'Thiodendron' sulfur mats in different saline environments.
2001-03
Sequence information, distinction and quantitation of C-terminal leucine and isoleucine in ternary complexes of tripeptides with Cu(II) and 2,2'-bipyridine.
2001-03
Identification of a novel single-nucleotide polymorphism (Val554Ile) and definition of eight common alleles for human IL4RA exon 11.
2001-03
Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
2001-02-20
The Val-210-Ile pathogenic Creutzfeldt-Jakob disease mutation increases both the helical and aggregation propensities of a sequence corresponding to helix-3 of PrP(C).
2001-01-12
Homoserine dehydrogenase from Saccharomyces cerevisiae: kinetic mechanism and stereochemistry of hydride transfer.
2001-01-12
Characterization of yeast homoserine dehydrogenase, an antifungal target: the invariant histidine 309 is important for enzyme integrity.
2001-01-12
Lysine metabolism in higher plants.
2001
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
2001
Metabolism of branched-chain amino acids in starved rats: the role of hepatic tissue.
2001
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: in combination with L-valine and L-leucine
2.9g of L-isoleucine over 6 months
Route of Administration: Oral
Primary cultures of peripheral blood mononuclear cells were rinsed with PBS and harvested in phosphate buffer pH 7.4 (50 mmol/L KH2PO4, 1 mmol/L EGTA, 150 mmol/L sucrose). The reaction was started by the addition of a lucigenin mixture 5 μmol/L) and NADPH (100 μmol/L) (Sigma-Aldrich) to the protein sample in a final volume of 250 μL. Branched-chain amino acids were prepared as a mixture of leucine, isoleucine and valine at 0.2–12 mmol/L Cells were exposed to increasing concentrations of BCAA (4–12 mmol/L) for 1 h Chemiluminescence was determined every 2.4 s for 3 min in a microtiter plate luminometer (Enspire Perkin Elmer). Basal activity in the absence of NADPH was subtracted from each reading and normalized to protein concentration.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:36:20 GMT 2025
Edited
by admin
on Mon Mar 31 17:36:20 GMT 2025
Record UNII
04Y7590D77
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOLEUCINE
EP   HSDB   II   INCI   INN   MART.   MI   USAN   USP   VANDF   WHO-DD  
USAN   INCI   INN  
Official Name English
L-ISOLEUCINE
FCC   USP-RS  
Preferred Name English
ISOLEUCINE [II]
Common Name English
(S-(R*,R*))-2-AMINO-3-METHYLPENTANOIC ACID
Systematic Name English
L-ISOLEUCINE [USP-RS]
Common Name English
Isoleucine [WHO-DD]
Common Name English
ISOLEUCINE, L-
Systematic Name English
ISOLEUCINE [USP MONOGRAPH]
Common Name English
NSC-46708
Code English
(2S,3S)-2-AMINO-3-METHYLPENTANOIC ACID
Systematic Name English
ISOLEUCINE [MI]
Common Name English
ISOLEUCINE [MART.]
Common Name English
L-ISOLEUCINE [FCC]
Common Name English
VALINE IMPURITY B [EP IMPURITY]
Common Name English
ISOLEUCINE [VANDF]
Common Name English
FEMA NO. 4675
Code English
ISOLEUCINE [USAN]
Common Name English
ISOLEUCINE [EP MONOGRAPH]
Common Name English
ISOLEUCINE [HSDB]
Common Name English
LEUCINE IMPURITY A [EP IMPURITY]
Common Name English
isoleucine [INN]
Common Name English
ILE
Code English
L-ISOLEUCINE [JAN]
Common Name English
Classification Tree Code System Code
LOINC 25938-2
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 2510-6
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 53397-6
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47673-9
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 20648-2
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 44329-1
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 53393-5
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
JECFA EVALUATION L-ISOLEUCINE
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 56689-3
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 57996-1
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
FDA ORPHAN DRUG 93095
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 2509-8
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
DSLD 173 (Number of products:424)
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 53152-5
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47672-1
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 26965-4
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 55929-4
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 53154-1
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 32251-1
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
FDA ORPHAN DRUG 33588
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 32252-9
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 17029-0
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 30052-5
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47671-3
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 2507-2
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 32783-3
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 22714-0
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 53153-3
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47676-2
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47674-7
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 15138-1
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 13765-3
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 25939-0
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
DSLD 2415 (Number of products:1910)
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 22659-7
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 26730-2
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 45214-4
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 2508-0
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 25450-8
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
NCI_THESAURUS C68442
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
CFR 21 CFR 172.320
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 15131-6
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 9743-6
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47675-4
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 72899-8
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 22706-6
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 13402-3
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
LOINC 47677-0
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
Code System Code Type Description
DAILYMED
04Y7590D77
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
CHEBI
17191
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
FDA UNII
04Y7590D77
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
SMS_ID
100000091969
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
NCI_THESAURUS
C29598
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
RS_ITEM_NUM
1349502
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
PUBCHEM
6306
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
DRUG BANK
DB00167
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
WIKIPEDIA
ISOLEUCINE
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
INN
6164
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
HSDB
7798
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
EVMPD
SUB08320MIG
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
RXCUI
6033
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID1047441
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
CHEBI
24898
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
EVMPD
SUB21979
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
DRUG CENTRAL
4129
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
CHEBI
30009
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
CHEBI
58045
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
MERCK INDEX
m6495
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY Merck Index
JECFA MONOGRAPH
2095
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
CAS
73-32-5
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
NSC
46708
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-798-2
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
ChEMBL
CHEMBL1233584
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
MESH
D007532
Created by admin on Mon Mar 31 17:36:20 GMT 2025 , Edited by admin on Mon Mar 31 17:36:20 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Useful in the treatment of renal and hepatic disorders characterized by protein intolerance leading to deficiencies of various essential and semi-essential amino acids in the body
Related Record Type Details
PARENT -> IMPURITY
impurity A at 570 nm: maximum 0.8 per cent
CHROMATOGRAPHIC PURITY (TLC)
EP
PARENT -> IMPURITY
impurity B at 570 nm
CHROMATOGRAPHIC PURITY (TLC)
EP
Related Record Type Details
ACTIVE MOIETY